Diabetes

An introduction to the Joslin Clinical Analytic Tool, a new diabetes measure developed to adjust for the variety in patient mix and better inform clinicians which interventions will work best.

On Tuesday, March 22, 1-2 pm ET, The American Journal of Managed Care will host a tweetchat with Joslin Diabetes Center to discuss diabetes management and the current status of diabetes performance measures.

Michael Castagna, PharmD, MBA, has significant sales and marketing experience, but does he have enough time or money to rescue Afrezza?

Did MannKind misjudge consumer demand, or are barriers from payers to blame for Afrezza's woes? A feature outlining the misfortunes and future plans for the only inhaled insulin on the market.

Both the authors and the writer of an editorial said obese women should be warned of potential risks, but that with absolute stroke risk low, they should not be denied access to contraception.

The top stories in managed care this week included a proposed new payment model for Medicare Part B and the swift criticism that followed the announcement, findings on variation in cost based on site of care, and cardiovascular results for Victoza.

The proposals recommend modernizing policies across the healthcare industry, including the drug discovery and development process, promoting value-driven healthcare, increasing the consumer voice, and addressing market distortions.

Improved health technologies will help physicians better monitor patients with chronic conditions so that those patients can receive more effective care and will help build a bridge between what has been reported as effective in literature and applying it to the patient, explained Lonny Reisman, MD, founder and CEO of HealthReveal.

Integrated approaches using electronic health records, clinical decision support, and patient-controlled technologies may help improve the appropriate use of medication as well as the management of type 2 diabetes.

The study revealed large disparities in prediabetes levels among young adults by race and ethnicity, underscoring the challenge for public officials in finding solutions to poor access to healthy food and safe places for children to play.

With the movement toward rewarding doctors based on how well they deliver care comes the question: how to adjust for the different patients doctors see? Authors writing in The American Journal of Managed Care reviewed 13 different studies and made a startling finding-most factors we assume merit adjustments in diabetes care do not, based on evidence thus far.

The study found that being out of shape aerobically and having poor muscle strength made a young man 3 times more likely to develop diabetes as he got older.

A study conducted in Denmark identified an inverse association between controlling diabetes, through diet or oral medications, and breast density.

It's no surprise that researchers were unable to come to firm conclusions about the cardiovascular safety of Contrave based on partial results. An accompanying editorial in JAMA finds that a repeat of the LIGHT saga could force FDA to demand full safety data before approval.

The LEADER trial is the latest in a recent wave of cardiovascular outcomes trials now required by FDA for diabetes and obesity therapies. Full results will be reported in June at the meeting of the American Diabetes Association.

The study, published in the journal Nature, found that mice fed a high-fat diet had more stem cells that behaved differently outside their natural environment, showing signs that would be associated with tumor growth.

The study is the most recent to suggest that obesity leads to alterations in brain function in the area that regulates memory.

The Diabetes Telehealth Network has a goal of enrolling 200 patients and providing remote care for 18 months. Results from the first 100 patients show not a single readmission; the project found 18 cases of diabetic retinopathy that would have otherwise been missed.

The authors said the incidence rates in type 1 diabetes compared with type 2 show that insulin treatment is not to blame for increased cancer rates.

Geisinger's all-or-none diabetes bundled system of care implemented in routine primary care settings was associated with sustained long-term total cost savings.

The results at 2 years show that aflibercept, marketed as Eylea, have benefits over bevacizumab for patients who start treatment with vision of 20/50 or worse.

The top stories in managed care this week include findings on cancer survival disparities, CVS Health claimed drug spending growth slowed in 2015, and Horizon Blue Cross Blue Shield of New Jersey's OMNIA plan is interfering with existing patient-centered medical homes.

Mann spent $1 billion of his own money to bring Afrezza to market. The Los Angeles Times reported he died in Las Vegas.

A new proposal from researchers at MIT and Dana-Farber offers a remedy for patients to cover high healthcare costs: securitized consumer healthcare loans.

Unlike former Mayor Michael Bloomberg's attempt to limit soda portions, this rule gives consumers information and lets them make their own decisions. Such measures have had more support from the public and the courts.